Patents
Literature
40 results about "Neuroactive steroid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neurosteroids, also known as neuroactive steroids, are endogenous or exogenous steroids that rapidly alter neuronal excitability through interaction with ligand-gated ion channels and other cell surface receptors. The term neurosteroid was coined by the French physiologist Étienne-Émile Baulieu and refers to steroids synthesized in the brain. The term, neuroactive steroid refers to steroids that can be synthesized in the brain, or are synthesized by an endocrine gland, that then reach the brain through the bloodstream and have effects on brain function. The term neuroactive steroids was first coined in 1992 by Steven Paul and Robert Purdy. In addition to their actions on neuronal membrane receptors, some of these steroids may also exert effects on gene expression via nuclear steroid hormone receptors. Neurosteroids have a wide range of potential clinical applications from sedation to treatment of epilepsy and traumatic brain injury. Ganaxolone, a synthetic analog of the endogenous neurosteroid allopregnanolone, is under investigation for the treatment of epilepsy.
Neuroactive steroids for treatment of CNS-related disorders
The present disclosure relates to methods of treating major depressive disorder (MDD) or postpartum depression (PPD) in a subject in need thereof with a combination of Compound (1) and an additional antidepressant, followed by continued administration of the additional antidepressant.
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids for treatment of gastrointestinal diseases or conditions
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids, compositions and uses thereof
Described herein are steroids of Formula (I):and pharmaceutically acceptable salts thereof, wherein R1, R2a, R2b, R3, R4, R5a, R5b, R6, and Z are as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids, compositions, and uses thereof
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids and their methods of use
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids, compositions, and uses thereof
Owner:SAGE THERAPEUTICS LLC
3. Alpha-hydroxy, 17-beta-C(O)-N-aryl-substituted neuroactive steroids and compositions thereof
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids and methods of use thereof
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids, compositions, and uses thereof
InactiveUS20260116911A1Organic active ingredientsNervous disorderWithdrawal syndromeSubstance abuser
Provided herein are 19-nor C3, 3-disubstituted steroids of Formula (I); and pharmaceutically acceptable salts thereof; wherein R1, R2, R3, and R4 are as defined herein, and A is a heteroaryl ring system comprising 3 or 4 nitrogens as defined herein. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related conditions, for example, treatment of sleep disorders, mood disorders, schizophrenia spectrum disorders, convulsive disorders, disorders of memory and / or cognition, movement disorders, personality disorders, autism spectrum disorders, pain, traumatic brain injury, vascular diseases, substance abuse disorders and / or withdrawal syndromes, and tinnitus.
Owner:SAGE THERAPEUTICS INC
Neuroactive steroid solid dispersion, solid dispersion composition, method for preparing same and use thereof, and drug comprising solid dispersion
PCT designated stageWO2026077307A1Organic active ingredientsPowder deliveryPlasticizerNeuroactive steroid
The present invention relates to the field of pharmaceutical technology, and in particular, to a neuroactive steroid solid dispersion, a solid dispersion composition, a method for preparing same and use thereof, and a medicament comprising the solid dispersion. The neuroactive steroid solid dispersion is obtained by melting and extruding a mixture of raw materials. In parts by mass, the mixture of raw materials comprises: 10 to 70 parts of a neuroactive steroid, 30 to 90 parts of a carrier material, and 0 to 60 parts of a plasticizer. The temperature of melting and extruding is < 160 °C. The neuroactive steroid in the neuroactive steroid solid dispersion is present in an amorphous state with a particle size of ≤ 200 nm, and features good oral bioavailability.
Owner:BEIJING HORICIN BIOTECHNOLOGY CO LTD
Neuroactive steroids and their methods of use
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids for treatment of gastrointestinal diseases or conditions
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
Owner:SAGE THERAPEUTICS INC
Neuroactive steroid formulations and methods of use thereof
Owner:SAGE THERAPEUTICS INC
Crystal Forms of Neuroactive Steroids
PendingJP2025523826AOrganic active ingredientsPowder deliveryNeuroactive steroidPharmaceutical medicine
The present disclosure relates to a crystalline solid form of Compound 1. The present disclosure also provides a method for preparing the crystalline solid form of Compound 1. In a first aspect, the present disclosure provides a crystalline form of Compound 1, wherein the crystalline form is Crystal Form C, and Form C is characterized by an XRPD pattern comprising peaks at 12.0 ± 0.2, 15.1 ± 0.2, and 21.3 ± 0.2 degrees 2θ. In a second aspect, the present disclosure provides a solid dosage form comprising Crystal Form C of Compound 1 disclosed herein and at least one pharmaceutically acceptable carrier. JPEG2025523826000018.jpg3067
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids and compositions thereof
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids and pharmaceutical compositions containing the same
ActiveCN115244065BOrganic active ingredientsNervous disorderBipolar mood disorderNeuroactive steroid
The present invention relates to novel neuroactive steroids (NAS). The present invention also relates to pharmaceutical compositions comprising the neuroactive steroids (NAS) and salts thereof. The pharmaceutical compositions can be used to prevent and / or treat CNS conditions or diseases associated with GABA regulation, such as depression, bipolar disorder, dementia, Huntington's disease, Parkinson's disease, and the like. The present invention also relates to methods for treating CNS disorders in subjects in need thereof.
Owner:BRII BIOSCIENCES LTD
Neuroactive steroids and their methods of use
Provided herein is a compound of Formula (I) or a pharmaceutically acceptable salt thereof, wherein R19, R5, R3a, R1a, R1b, R2a, R2b, R4a, R4b, R6a, R6b, R7a, R7b, R11a, R11b, R12a, R12b, R18, RD, and q are defined herein. L is selected from the group consisting of: wherein A indicates the point of attachment at C17 and wherein X is selected from the group consisting of —C(O)N(R55a)(R55b), —N(R55a)(R55b), —N(R55b)C(O)(R55a), and R55C wherein R55c is carbon-bound substituted or unsubstituted heteroaryl or substituted or unsubstituted aryl. Also provided herein are pharmaceutical compositions comprising a compound of Formula (I) and methods of using the compounds, e.g., in the treatment of CNS-related disorders.
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids for treatment of gastrointestinal diseases or conditions
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
Owner:SAGE THERAPEUTICS INC
3.alpha.-hydroxy-17.beta.-amide neuroactive steroids and compositions thereof
Owner:SAGE THERAPEUTICS LLC
Compositions and methods for treating CNS disorders
Described herein are neuroactive steroids of the Formula (I): or a pharmaceutically acceptable salt thereof; wherein, R1, R2a, R2b, R3 and A are as defined herein. Such compounds are envisioned, in certain embodiments, to behave as GABA modulators. The present invention also provides pharmaceutical compositions comprising a compound of the present invention and methods of use and treatment, e.g., such for inducing sedation and / or anesthesia.
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids substituted with cyclic groups at position 10 for treatment of CNS disorders
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids for treatment of gastrointestinal diseases or conditions
The present disclosure relates to methods of treating a gastrointestinal (GI) disease or condition in a subject in need thereof.
Owner:SAGE THERAPEUTICS INC
NEUROACTIVE STEROIDS, COMPOSITIONS AND USES THEREOF
Owner:SAGE THERAPEUTICS INC
Methods of treating epilepsy or status epilepticus
PendingUS20250161325A1Organic active ingredientsNervous disorderNeuroactive steroidComplex partial status epilepticus
Described herein are methods of treating epilepsy or status epilepticus, e.g., convulsive status epilepticus, e.g., early status epilepticus, established status epilepticus, refractory status epilepticus, super-refractory status epilepticus, e.g., super-refractory generalized status epilepticus; non-convulsive status epilepticus, e.g., generalized status epilepticus, complex partial status epilepticus; generalized periodic epileptiform discharges; periodic lateralized epileptiform discharges; a seizure, e.g., acute repetitive seizures, cluster seizures, the method comprising administering to the subject a neuroactive steroid.
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroids, compositions, and uses thereof
Owner:SAGE THERAPEUTICS LLC
9(11)-unsaturated neuroactive steroids and methods of use thereof
ActiveCN113227114BOrganic active ingredientsAndrostane derivativesNeuroactive steroidPharmaceutical drug
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids substituted in position 10 with a cyclic group for use in the treatment of CNS disorders
Owner:SAGE THERAPEUTICS INC
Neuroactive steroids and methods of use thereof
Owner:SAGE THERAPEUTICS LLC
Neuroactive steroid for the treatment of alzheimer's disease
The present disclosure relates to compositions, kits and methods of treating Alzheimer's disease comprising administering an NMD A receptor positive allosteric modulator or a CYP46A1 inhibitor.
Owner:SAGE THERAPEUTICS INC
Crystal form of neuroactive steroid derivative and use thereof
The present invention belongs to the technical field of medicine. Provided are a crystal form of a neuroactive steroid derivative and the use thereof. For the crystal form of the neuroactive steroid derivative (having a structure represented by formula (I)), the characteristic diffraction peaks in an X-ray powder diffraction pattern expressed as 2θ angles using Cu-Kα radiation include 11.450±0.200°, 15.724±0.200°, 19.040±0.200°, 22.955±0.200° and 24.975±0.200°. The crystal form has good flowability, no electrostatic phenomenon, high stability, and almost no hygroscopicity, and remains stable under high temperature, high humidity and light exposure conditions. The crystal form has a strong positive modulatory effect on a GABAA receptor, and has favorable pharmacokinetic properties and a favorable oral absorption rate. Therefore, the crystal form can be applied in the preparation of oral and other dosage forms of drugs with a high efficacy against diseases such as postpartum depression.
Owner:HUNAN MINGRUI PHARMACEUTICAL CO LTD